The history of Thiotriazolin® goes back about 40 years. Starting since the 1960s, the scientists of the Pharmaceutical Chemistry Department of Zaporizhia State Medical University, led by Professor I.A. Mazur, have been engaged in a target-oriented search for new biologically active substances. Research was conducted in cooperation with medical and biological departments of Zaporizhia Medical University (Departments of Pharmacology, Microbiology, Human Anatomy and Physiology), as well as the relevant departments of the National Pharmaceutical University, State Medicines Research Center and D. Halytskyi Lviv State Medical University. The research allowed to synthesize over 10 thousand new compounds.
In 1986, E-8252 compound (the future Thiotriazolin®) was selected as a promising potential medicinal product. The study of its pharmacological properties began in the Soviet era and continued in the independent Ukraine.

The molecule of Thiotriazolin® attracted the scientists’ attention primarily due to several important properties. Thiotriazolin® can increase cell survival in the setting of reduced oxygen supply (hypoxia), which is a key factor in various conditions. Thiotriazolin® restores normal metabolic processes in the cell, preserving its structural integrity. In addition, Thiotriazolin® protects the cell against the harmful substances generated in the body during oxygen starvation and activates the enzymes responsible for the breakdown of such substances. Another important characteristic of Thiotriazolin® is its ability to improve blood flow in the affected area.

Many human diseases are directly associated with impaired circulation resulting in hypoxia and cell death. The above diseases include, primarily, atherosclerosis which manifests itself as cerebrovascular accident, coronary heart disease / myocardial infarction or occlusive disease of the lower extremities, depending on various factors. As cells differ from organ to organ, their resistance to oxygen starvation differs accordingly. That is why, Thiotriazolin® is highly effective in some diseases and cannot be used in others.

The timeline of Thiotriazolin® history:

The whole battery of non-clinical studies was performed. The studies concentrated on the product’s toxicity, mutagenicity and tumorogenicity, clarifying its mechanism of action and chemical transformation in the body. The research was conducted by top professionals from the departments of Zaporizhia State Medical University and Kharkiv State Pharmaceutical University, led by Professors I.A. Mazur, V.V. Dunaiev, V.R. Stets, etc. The studies demonstrated that Thiotriazolin® is a highly effective medicinal product with antioxidant, membrane stabilizing, anti-ischemic and anti-arrhythmic activities. Moreover, Thiotriazolin® proved to have a positive effect on the hepatic function.
Leading scientists of Ukraine applied to the Pharmacological Committee of the MOH of Ukraine requesting approval of the product for clinical use.
Initial clinical trials and approval of Thiotriazolin® for use in practical medicine. Thiotriazolin® became the first drug to have been developed in Ukraine from scratch – from an idea to the finished product.
Production of Thiotriazolin® 1% and 2.5% solution for injections in ampoules and 100 mg tablets was launched at Halychfarm pharmaceutical factory.
A number of studies showing the benefits of Thiotriazolin® in myocardial infarction and angina were conducted.
By order of the Minister of Health of Ukraine, Thiotriazolin® was included in the list of essential medicinal products.
Approval of Thiotriazolin® in Belarus, Uzbekistan, Kazakhstan and Tajikistan.
Registration of Thiotriazolin® in the Azerbaijan Republic
Registration of Thiotriazolin® in the Russian Federation 
Continuing studies of Thiotriazolin® efficacy and safety compared to other metabolic drugs used in cardiology.
2010 Launch of Thiotriazolin® 200 mg tablets.

Copyright © 2023, Arterium Corporation